Platform insights and clinical experience guide development of Constellation Pharmaceuticals’ wholly owned lead product candidates: CPI-1205, which inhibits enhancer of zeste homolog 2, or EZH2, and CPI-0610, which inhibits bromodomain and extra terminal domain, or BET, proteins. The company believes that its approach to targeting these central gene regulatory mechanisms associated with cancer proliferation may enable it to provide therapeutic benefits to cancer patients.
Constellation’s integrated epigenetics platform includes a deep understanding of the biology of regulation of gene expression by epigenetic regulatory proteins, or epigenetic regulators, the development of small-molecule product candidates that selectively modulate their activity and the design of clinical development programs supported by novel biomarker strategies. The company is able to target a broad variety of epigenetic regulators using its platform and has generated development candidates acting against distinct classes of those regulators. It utilized its epigenetics platform to discover and design CPI-1205, CPI-0610 and CPI-0209, which is a second-generation EZH2 inhibitor, and continues to leverage this platform to develop these product candidates and to discover and develop additional product candidates.
Data as of: November 25, 2020 10:53 PM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.